CJC-1295 without DAC benefits include faster GH pulses and a shorter half-life than the DAC version. Compare research dosing, stacking, and safety here.
CJC-1295 without DAC is a research peptide studied for producing short, sharp growth hormone (GH) pulses instead of a continuous rise. The benefits most often reported in laboratory and animal work are a rapid onset of GH release, a secretion pattern that mirrors the body's natural overnight rhythm, and easier stacking with growth hormone-releasing peptides such as ipamorelin. CJC-1295 is not FDA-approved for human use in the United States, so everything below describes research findings, not an established medical treatment.
What CJC-1295 Without DAC Actually Is
CJC-1295 without DAC is also written as Mod GRF(1-29) or simply "no DAC." It is a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) with four substitutions that help it resist enzymatic breakdown in the bloodstream long enough to reach pituitary receptors.
The two versions differ by a single added group. CJC-1295 with DAC carries a Drug Affinity Complex that binds to albumin in blood, extending its half-life from roughly 30 minutes to about 6 to 8 days. CJC-1295 without DAC skips that modification and clears quickly.
Researchers asking what is cjc-1295 with dac vs without dac are usually really asking about timing: how long the peptide stays active and what that does to the GH and IGF-1 curve.
Main Benefits Studied With the No-DAC Version
Most reported advantages come from the peptide's short half-life rather than from a stronger effect. A short half-life means the pituitary receives a brief signal and then returns to baseline.
- Fast GH release. GH levels typically peak within 15 to 30 minutes of administration in animal models, producing a distinct pulse rather than a plateau.
- A more physiological pattern. Natural GH secretion happens in bursts, mostly during deep sleep. A rapid-clearing analog reproduces that burst more closely than a long-acting form does.
- Less "GH bleed." Constant GH elevation is sometimes called GH bleed. Because CJC-1295 without DAC clears in about half an hour, sustained elevation is far less likely.
- Easier timing. A short-acting peptide can be timed to sleep onset or to a fasted window, which researchers often prefer when studying pulsatile GH release.
- Straightforward stacking. It pairs logically with ghrelin-receptor agonists, since GHRH and ghrelin act on different receptors.
- Faster washout. A short half-life means the compound leaves the system quickly if a study needs to stop.
What CJC-1295 without DAC does not appear to do is drive the steady, day-long IGF-1 elevation associated with the DAC form. That distinction matters when a study is designed to isolate pulse frequency rather than total hormone exposure.
CJC-1295 With DAC vs Without DAC
| Feature | CJC-1295 Without DAC | CJC-1295 With DAC |
|---|---|---|
| Half-life | About 30 minutes | About 6 to 8 days |
| Albumin binding | No | Yes |
| GH pattern | Sharp, short pulses | Sustained elevation |
| Typical research frequency | 1 to 3 times daily | 1 to 2 times weekly |
| Common pairing | Ipamorelin, GHRP-2, GHRP-6 | Often studied alone |
| FDA status | Not approved for human use | Not approved for human use |
The cjc-1295 dac peptide benefits reported in research lean toward convenience and steadier IGF-1 levels. The no-DAC version trades that convenience for a cleaner pulse and faster clearance.
Stacking CJC-1295 Without DAC and Ipamorelin
Combining a GHRH analog with a ghrelin-receptor agonist is one of the most studied pairings in peptide research. CJC-1295 without DAC supplies the GHRH signal, while ipamorelin triggers a separate receptor pathway that can amplify the same GH pulse.
When people compare cjc-1295 ipamorelin with dac or without, the practical trade-off is pulse sharpness versus injection frequency. A no-DAC plus ipamorelin protocol usually means more frequent administration, while the DAC pairing means fewer injections.
Vials are frequently sold as cjc-1295 without dac 5mg ipamorelin 5mg, a 1:1 ratio blend. Ratio matters less than total exposure, and many researchers reconstitute and dose the two peptides separately so each one can be adjusted independently.
Dosage and Timing Reported in Research
No human dose of CJC-1295 without DAC has been established by any regulatory agency. The figures below reflect patterns reported in research literature and online discussion, not clinical guidance.
| Parameter | Reported Range |
|---|---|
| Single dose | About 100 to 200 mcg in research settings |
| Frequency | 1 to 3 times daily |
| Timing | Before sleep or in a fasted state |
| Cycle length | Commonly 8 to 12 weeks, then a break |
| Ratio with ipamorelin | Often 1:1 |
Search interest in cjc-1295 no dac dosage and cjc-1295 without dac dosage bodybuilding is high, but bodybuilding forums are not a reliable source of dosing information. Reported amounts vary widely, and no controlled human trial has confirmed effectiveness or safety at any dose.
Side Effects, Safety, and Legal Status
Reported side effects of GHRH analogs include injection-site irritation, flushing, headache, dizziness, fatigue, and water retention. Because any effective GHRH analog raises GH, it can also raise IGF-1 and influence blood sugar, which is especially relevant for people with diabetes or a history of cancer.
CJC-1295 is not FDA-approved for human use in the United States. It is sold as a research chemical, which means purity, sterility, and actual content are not verified by any regulator.
- Long-term human safety data for CJC-1295 does not exist.
- Unregulated vials may contain incorrect amounts or unrelated compounds.
- Anyone using GH-related substances should be monitored by a healthcare professional.
Bottom Line
CJC-1295 without DAC offers a short, sharp GH pulse, a secretion pattern closer to the body's natural rhythm, and easy stacking with ipamorelin. CJC-1295 with DAC offers a longer half-life and fewer injections. Both remain unapproved research compounds with no established human safety profile, and neither should be presented as a proven therapy.
Frequently Asked Questions
What are the main benefits of CJC-1295 without DAC?
In research settings, CJC-1295 without DAC produces a rapid growth hormone pulse, clears within about 30 minutes, and avoids the constant GH elevation seen with the DAC version. Those traits make it appealing for pulse-timing studies and for stacking with ipamorelin. No human clinical trial has confirmed any benefit in people.
How is CJC-1295 without DAC different from CJC-1295 with DAC?
The DAC version carries an albumin-binding group that extends its half-life to roughly 6 to 8 days, while the no-DAC version lasts about 30 minutes. The DAC form therefore creates steadier IGF-1 levels with fewer injections, and the no-DAC form creates sharper, shorter pulses. Both are unapproved for human use in the United States.
Is CJC-1295 without DAC legal and safe?
CJC-1295 is not FDA-approved for human use in the United States and is generally sold only as a research chemical. Reported side effects include injection-site irritation, flushing, headache, and water retention, and long-term human safety data does not exist. Talk with a healthcare professional before considering any peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.